Mezigdomide Triplet Improves PFS in R/R Multiple Myeloma

Published Date: 30 Jun 2026

A phase 3 trial evaluates the efficacy of mezigdomide plus carfilzomib and dexamethasone vs carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Do Anatomy Atlases Reflect Social Inequalities?

2.

In Resectable Lung Cancer, Perioperative Nivolumab Increases EFS.

3.

Mammography with AI support is a secure method for detecting breast cancer.

4.

QOL Maintained With Giredestrant Combo in Advanced BC

5.

Talc Powder Not Linked to Lung Cancer in Women


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot